Asset profile
belapectin
Protein / enzyme therapeutic
Evidence outlook
Phase 2/3 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT04365868) was terminated, and no study is currently active on the registry. Earlier completed evidence carries a partial signal signal; the stopped study adds none. Check the registry record for the sponsor's stated reason.
NAVIGATE (NCT04365868): This was a randomized, double-blind, placebo-controlled trial that measured a real clinical marker of disease progression, new esophageal varices, and numerically fewer patients developed varices on belapectin than on placebo. However, the registry record does not include a statistical significance test for this difference, and the gap between arms was not large enough to be judged as a positive result on its own, so whether belapectin truly worked remains unresolved.
Also in development:NASH Cirrhosis · Phase 2/3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
32 competitors in this universe: 1 direct rival (same mechanism and indication), 2 same-class, 29 same-indication; 11 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Belapectin: this drug | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| GR-MD-02 | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| TB006 | Phase 2 | Monoclonal antibody | Galectin-3 | ||
| SIF001 | Phase 1 | Monoclonal antibody | Galectin-3 | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| ALN-HSD | Phase 2 | RNA / oligonucleotide | HSD17B13 |
…and 17 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.